Candel Therapeutics ( (CADL) ) has shared an update.
On February 25, 2025, Candel Therapeutics announced positive final overall survival data from its phase 2 clinical trial of CAN-2409 in non-metastatic pancreatic cancer. The trial showed that patients treated with CAN-2409 had a median overall survival of 31.4 months compared to 12.5 months in the control group, with a favorable safety profile. This data highlights the potential of CAN-2409 to significantly improve survival in pancreatic cancer, supporting its further development in a larger, late-stage trial.
More about Candel Therapeutics
Candel Therapeutics is a clinical stage biopharmaceutical company focused on developing off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. The company has established two clinical stage multimodal biological immunotherapy platforms based on novel, genetically modified adenovirus and HSV gene constructs.
YTD Price Performance: 21.91%
Average Trading Volume: 4,200,587
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $487.5M
For detailed information about CADL stock, go to TipRanks’ Stock Analysis page.